Severe psoriasis treated with a new macrolide: Everolimus

E. Frigerio, M. D. Colombo, C. Franchi, A. Altomare, C. Garutti, G. F. Altomare

Research output: Contribution to journalArticlepeer-review


Psoriasis is an immune-mediated disease with a chronic relapsing course, and the particularly severe forms that are refractory to traditional therapies are often difficult to manage. Everolimus (Certican®; Novartis, Basel, Switzerland) is a new rapamycin-derived macrolide that is used in the prophylaxis of rejection in heart and kidney transplant patients. The mechanism underlying its immunosuppressant and antiproliferative activity is different from, but complementary to, that of calcineurin inhibitors such as ciclosporin. We describe a woman with severe psoriasis treated with everolimus combined with subtherapeutic doses of ciclosporin.

Original languageEnglish
Pages (from-to)372-374
Number of pages3
JournalBritish Journal of Dermatology
Issue number2
Publication statusPublished - Feb 2007


  • Ciclosporin
  • Everolimus
  • Psoriasis

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Severe psoriasis treated with a new macrolide: Everolimus'. Together they form a unique fingerprint.

Cite this